# Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

> **NCT07660835** · PHASE2 · RECRUITING · sponsor: **Galderma R&D** · enrollment: 35 (estimated)

## Conditions studied

- Moderate-to-Severe Atopic Dermatitis

## Interventions

- **DRUG:** Nemolizumab

## Key facts

- **NCT ID:** NCT07660835
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2028-07-15
- **Final completion:** 2028-07-15
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660835, "Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*